Skip to main content
. 2019 Jun 4;10(38):3760–3806. doi: 10.18632/oncotarget.26940

Table 6. Design of genetic and epigenetic multiple drugs for the therapeutic treatment of advanced stage LSCC.

Advanced stage LSCC
Drug target
CDH3, CHIC2, TUBB3, LIN7C, YBX1, FN1, ITGA8, TGFB1, ERBB4, DDX5, EMR2, MSN, CHD3, FOXO3, GATA3
Drug molecule
Drug Name Repressed drug target Activated drug target
Clomipramine CDH3, CHIC2, LIN7C, YBX1 DDX5, EMR2, ERBB4, FN1, FOXO3, GATA3, ITGA8, TGFB1
Rolipram CDH3, TUBB3 DDX5, EMR2, ERBB4, FN1, GATA3, ITGA8, MSN, TGFB1, CHD3
Procainamide TUBB3, YBX1 DDX5, EMR2, ERBB4, FN1, GATA3, ITGA8, MSN, TGFB1, CHD3

Chemical structures of multiple-molecule drug

graphic file with name oncotarget-10-3760-i006.jpg

Through therapeutic treatment using the proposed genetic and epigenetic multiple-molecule drug, the proteins with significantly higher expression in the advanced stage (CDH3, CHIC2, TUBB3, LIN7C, and YBX1) can be repressed, and proteins with significant lower expression in the advanced stage (FN1, ITGA8, TGFB1, ERBB4, DDX5, EMR2, MSN, CHD3, FOXO3, and GATA3) can be activated to facilitate the restoration of advanced stage LSCC to normal lung cells.